Does the cash reach the readout? What 102 Boston-area biotechs filed for Q2 2026

Every quarter, the listed biotechs headquartered in Cambridge and the surrounding cluster tell the SEC how much cash they hold and how much they spent. Most of them also register their trials on ClinicalTrials.gov with an expected primary completion date. Put the two side by side and you can answer, from the outside, the question every board in the neighborhood is asking: does the money last until the data arrives?

The numbers below come from the Cambridge biotech tracker on this site, built from 10-Q and 10-K filings for the quarter ended June 30, 2026, and from each company's own interventional studies where it is the lead sponsor. The snapshot was taken on October 1, 2026.

The neighborhood in five numbers

• 102 listed biotech and pharma companies in the cluster, 28 of them headquartered in Cambridge itself.
• A median runway of 30 months at the last four quarters' burn.
• 19 companies with less than twelve months of cash, and 38 with less than twenty four.
• $18.9 billion of net financing inflows over the last twelve months, with 86 of the 102 bringing in more than they repaid.
• 14 companies whose latest filing includes going concern language, and 6 that disclosed a material weakness in internal control.

A median of 30 months is a healthy number. It reflects a year in which most companies that needed money were able to raise it. But medians hide the tail, and in biotech the tail is where the hard conversations happen.

Cash against the next catalyst

For 73 of the 102 companies, the tracker can identify a next catalyst: the earliest expected primary completion of an active, company sponsored trial, or an FDA action date the company has disclosed. Extension studies, healthy volunteer studies, and post approval trials are excluded because they rarely move a valuation. Comparing that date to runway gives four outcomes.

• 54 companies have cash for at least six months past the catalyst. Among companies that burn cash and have a dated catalyst, the median cushion past it is about 22 months.
• 9 companies are self funding on an operating cash flow basis, so the catalyst does not depend on the bank balance.
• 3 companies reach the catalyst with less than six months to spare.
• 7 companies run out of cash before the catalyst, at their current burn.

The last two groups are small, ten companies in all, but they are the ones whose next financing will be negotiated on a deadline rather than on data. Six months of cushion is the floor because that is roughly how long a financing takes from first meeting to closing. Below it, investors know the company has to close, and the terms reflect that.

Where going concern shows up

Of the 14 companies with going concern language in their latest filing, 11 have less than twelve months of runway on the tracker's measure. That is close to what the accounting rules predict. Management has to assess whether cash covers the twelve months after the financial statements are issued, and a financing that has not closed generally cannot be counted toward that. A company with ten months of cash and a raise planned after its readout will usually have to disclose substantial doubt, however strong the program.

Of the other three, one shows more than six years of runway, one generated operating cash over the last four quarters, and one has too little reported data to compute runway at all. Those are a useful reminder of what the outside view misses: debt maturities, covenants, contingent obligations, or a planned step up in spending that trailing burn does not yet show.

What this means if you are on the inside

Investors and partners can now run this comparison on your company in a few minutes, from public data. If your own model shows a different answer, because a cost reduction is underway or a trial timeline has moved, the board and the next investor should hear that from you, with the support behind it, before they work it out themselves. The three numbers that matter are months to readout, cash at readout, and runway after readout. If you report those monthly, nobody outside the company will ever know more about your position than your board does.